Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
Dhinesh Selvaraju, Clinical Research Assistant at Yuva Intern by Henry Harvin, shared on LinkedIn:
”Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication of allogeneic HSCT characterized by:
- Endothelial injury and microvascular thrombosis
- Microangiopathic hemolytic anemia
- Consumptive thrombocytopenia
- Progressive multi-organ dysfunction
On December 24, 2025, the U.S. Food and Drug Administration approved narsoplimab-wuug (Yartemlea; Omeros Corporation) – the first and only approved treatment for TA-TMA in adults and pediatric patients aged two years and older.
MECHANISM OF ACTION
Narsoplimab-wuug is a first-in-class human IgG4 monoclonal antibody targeting MASP-2 (Mannan-binding lectin-Associated Serine Protease-2).
How it works:
- Selectively inhibits MASP-2, the primary effector enzyme of the lectin complement pathway
- Blocks lectin pathway-mediated complement deposition on damaged microvascular endothelium
- Interrupts the downstream cascade of thrombus formation, platelet consumption, and hemolysis
- Critically preserves the classical and alternative complement pathways, maintaining essential host immune defense in immunocompromised transplant recipients
Triggers of lectin pathway activation in TA-TMA include:
- Transplant conditioning regimens
- Graft-versus-host disease (GVHD)
- Calcineurin inhibitor toxicity
- Viral infections post-transplant
CLINICAL EVIDENCE
Approval was based on a single-arm, open-label pivotal study supplemented by an expanded access program (EAP).
Pivotal Study (n = 28 adult patients):
- TMA complete response (CR) rate: 61%
- 100-day survival rate from TA-TMA diagnosis: 73%
- Comparator analysis: approximately 3-fold lower mortality risk vs external historical control cohorts
Expanded Access Program (n = 19 evaluable patients; 6 pediatric, 13 adult):
- CR rate: 68%
- 100-day survival rate: 74%
SAFETY AND MONITORING
Key adverse reactions:
- Serious infections — most clinically significant risk, consistent with the immunocompromised transplant population
- Monitoring parameters: CBC, LDH, RFT
Notable: The FDA did not mandate a Boxed Warning or REMS for Yartemlea.
Full prescribing information should be reviewed prior to clinical use.
WHY THIS APPROVAL MATTERS
This approval represents a paradigm shift in TA-TMA management.
For decades, clinicians relied solely on:
- Calcineurin inhibitor dose reduction (first-line supportive measure)
- Plasma exchange (limited evidence, no approval)
- Defibrotide (off-label use, no formal TA-TMA indication)
REFERENCES
1. U.S. Food and Drug Administration. FDA approves narsoplimab-wuug (Yartemlea) for hematopoietic stem cell transplant-associated thrombotic microangiopathy. December 24, 2025.
2. Omeros Corporation.”
Stay updated with Hemostasis Today.
-
May 18, 2026, 13:02Paris Margaritis: Native Cellular Biology and the Future of Durable Hemophilia A Gene Therapy
-
May 18, 2026, 12:48Ilenia Calcaterra: Impact of Pain on Severe Haemophilia A Patients Receiving Emicizumab Prophylaxis
-
May 18, 2026, 08:12Perioperative Anticoagulation Management Isn’t a Checklist – Thrombosis Canada
-
May 18, 2026, 08:04Sophia Delicou: Iron Chelation Plateaus and Organ-Specific Iron Distribution in β-Thalassemia
-
May 18, 2026, 08:04Comprehensive Analysis of Patients With Prior Negative Genetic Testing for Wilson Disease – JHEP Reports
-
May 18, 2026, 08:022026 ITP Annual Patients’ Convention – ITP Support Association
-
May 18, 2026, 08:02Thomas Rocco Jr.: World Hypertension Day and the Future of Cardiovascular Prevention
-
May 18, 2026, 05:02Sandeep De: Omicron Infection Confirmed to Raise Blood Clot Risk for 6 Months
-
May 18, 2026, 04:52Abdessamia Gandoul: EHA Bedside Hematology Rapid Reference Guide Is Now Live